HomeExamplesMCP & ModelsResearchDocumentationLoginBook a demo
HomeExamplesMCP & ModelsResearchDocumentationLoginBook a demo

Cothera Bioscience

Ownership
Private
Therapeutic Areas
Oncology
Stage
Phase 1
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Small molecules

Cothera Bioscience General Information

PC-002 received FDA Fast Track Designation for Burkitt Lymphoma in October 2024. The company will present clinical results from the PC002-01 trial at the 2024 American Society of Hematology annual meeting.

Contact Information

Website
https://cotherabio.com/
Primary Industry
Biotech
Corporate Office
San Francisco, California
United States

Drug Pipeline

PC-002
Phase 1
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Cothera Bioscience's pipeline data

Book a demo

Key Partnerships

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Cothera Bioscience Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Cothera Bioscience's complete valuation and funding history, request access »

Cothera Bioscience Financial Metrics

See full profile
Book a demo
OverviewDrug PipelineTechnologiesPartnershipsFundingCompetitorsAnalysisPatentsLicensing Deals